Foreign-Trade Zone (FTZ) 29; Authorization of Production Activity; Catalent Pharma Solutions, LLC; (Nonsteroidal Antiandrogen Tablets); Winchester, Kentucky, 82971 [2024-23754]

Download as PDF Federal Register / Vol. 89, No. 199 / Tuesday, October 15, 2024 / Notices Friday, October 18, 2024, 10:00 a.m. EST. ADDRESSES: Meeting to take place virtually and is open to the public via livestream on the Commission’s YouTube page: https:// www.youtube.com/user/USCCR/videos. FOR FURTHER INFORMATION CONTACT: Joe Kim: 202–376–8371; publicaffairs@ usccr.gov. DATES: In accordance with the Government in Sunshine Act (5 U.S.C. 552b), the Commission on Civil Rights is holding a meeting to discuss the Commission’s business for the month. This business meeting is open to the public. Computer assisted real-time transcription (CART) will be provided. The web link to access CART (in English) on October 10, 2024, is https://www.streamtext.net/player? event=USCCR. Please note that CART is text-only translation that occurs in real time during the meeting and is not an exact transcript. I. Approval of Agenda II. Business Meeting A. Presentation by New Hampshire Advisory Committee Chair on Released Reports and Memorandum on Solitary Confinement B. Presentation by South Dakota Advisory Committee Chair on Released Reports and Memorandum on Voting Rights and Access C. Presentation by Tennessee Advisory Committee Chair on Released Reports and Memorandum on Civil and Voting Rights D. Management and Operations • Staff Director’s Report III. Adjourn Meeting SUPPLEMENTARY INFORMATION: States, to expedite and encourage foreign commerce, and for other purposes,’’ and authorizes the ForeignTrade Zones Board to grant to qualified corporations the privilege of establishing foreign-trade zones in or adjacent to U.S. Customs and Border Protection ports of entry; Whereas, the Board’s regulations (15 CFR part 400) provide for the establishment of subzones for specific uses; Whereas, the City of Phoenix, grantee of Foreign-Trade Zone 75, has made application to the Board for an expansion of Subzone 75C on behalf of Intel Corporation to include a site located in Phoenix, Arizona (FTZ Docket B–33–2024, docketed June 13, 2024); Whereas, notice inviting public comment has been given in the Federal Register (89 FR 51873, June 20, 2024) and the application has been processed pursuant to the FTZ Act and the Board’s regulations; and, Whereas, the Board adopts the findings and recommendations of the examiners’ memorandum, and finds that the requirements of the FTZ Act and the Board’s regulations are satisfied; Now, therefore, the Board hereby approves the expansion of Subzone 75C on behalf of Intel Corporation located in Phoenix, Arizona, as described in the application and Federal Register notice, subject to the FTZ Act and the Board’s regulations, including section 400.13. Dated: October 9, 2024. Dawn Shackleford, Executive Director of Trade Agreements Policy & Negotiations, Alternate Chairman, Foreign-Trade Zones Board. Dated: October 10, 2024. Zakee Martin, USCCR Special Assistant to the Staff Director. [FR Doc. 2024–23753 Filed 10–11–24; 8:45 am] [FR Doc. 2024–23843 Filed 10–10–24; 4:15 pm] DEPARTMENT OF COMMERCE BILLING CODE 3510–DS–P BILLING CODE P Foreign-Trade Zones Board [B–34–2024] DEPARTMENT OF COMMERCE Foreign-Trade Zone (FTZ) 29; Authorization of Production Activity; Catalent Pharma Solutions, LLC; (Nonsteroidal Antiandrogen Tablets); Winchester, Kentucky Foreign-Trade Zones Board [Order No. 2168] khammond on DSKJM1Z7X2PROD with NOTICES Approval of Expansion of Subzone 75C; Intel Corporation; Phoenix, Arizona Pursuant to its authority under the Foreign-Trade Zones Act of June 18, 1934, as amended (19 U.S.C. 81a–81u), the Foreign-Trade Zones Board (the Board) adopts the following Order: Whereas, the Foreign-Trade Zones (FTZ) Act provides for ‘‘. . . the establishment . . . of foreign-trade zones in ports of entry of the United VerDate Sep<11>2014 16:35 Oct 11, 2024 Jkt 265001 On June 11, 2024, Catalent Pharma Solutions, LLC, submitted a notification of proposed production activity to the FTZ Board for its facility within FTZ 29, in Winchester, Kentucky. The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the Federal Register inviting public comment (89 FR 52022, June 21, 2024). On October 9, 2024, the applicant PO 00000 Frm 00003 Fmt 4703 Sfmt 4703 82971 was notified of the FTZ Board’s decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board’s regulations, including section 400.14. Dated: October 9, 2024. Elizabeth Whiteman, Executive Secretary. [FR Doc. 2024–23754 Filed 10–11–24; 8:45 am] BILLING CODE 3510–DS–P DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [B–52–2024] Foreign-Trade Zone (FTZ) 235, Notification of Proposed Production Activity; Renaissance Lakewood, LLC; (Prescription Nasal Spray Products); Lakewood, New Jersey The Township of Lakewood, grantee of FTZ 235, submitted a notification of proposed production activity to the FTZ Board (the Board) on behalf of Renaissance Lakewood, LLC (Renaissance) for Renaissance’s facilities in Lakewood, New Jersey within FTZ 235. The notification conforming to the requirements of the Board’s regulations (15 CFR 400.22) was received on September 30, 2024. Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material/ component and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board’s website—accessible via www.trade.gov/ ftz. The proposed finished products include calcitonin gene-related peptide receptor antagonist (prescription nasal spray-packaged) and calcitonin generelated peptide receptor antagonist (prescription nasal spray-unpackaged) (duty-free). The proposed foreign-status material/ component includes zavegepant hydrochloride (active pharmaceutical ingredient) (duty rate of 6.5%). The request indicates that certain materials/ components are subject to duties under section 301 of the Trade Act of 1974 (section 301), depending on the country of origin. The applicable section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41). E:\FR\FM\15OCN1.SGM 15OCN1

Agencies

[Federal Register Volume 89, Number 199 (Tuesday, October 15, 2024)]
[Notices]
[Page 82971]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-23754]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-34-2024]


Foreign-Trade Zone (FTZ) 29; Authorization of Production 
Activity; Catalent Pharma Solutions, LLC; (Nonsteroidal Antiandrogen 
Tablets); Winchester, Kentucky

    On June 11, 2024, Catalent Pharma Solutions, LLC, submitted a 
notification of proposed production activity to the FTZ Board for its 
facility within FTZ 29, in Winchester, Kentucky.
    The notification was processed in accordance with the regulations 
of the FTZ Board (15 CFR part 400), including notice in the Federal 
Register inviting public comment (89 FR 52022, June 21, 2024). On 
October 9, 2024, the applicant was notified of the FTZ Board's decision 
that no further review of the activity is warranted at this time. The 
production activity described in the notification was authorized, 
subject to the FTZ Act and the FTZ Board's regulations, including 
section 400.14.

    Dated: October 9, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-23754 Filed 10-11-24; 8:45 am]
BILLING CODE 3510-DS-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.